Bachem Holding AGBCHMF 91 Current Ratio is 1.79 as of Dec. 2025, which is 35% below its 10-year median of 2.75. GuruFocus rates BCHMF with a GF Score™ of 91/100 and a GF Value™ of $98.14 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 1,417 Biotechnology companies, Bachem Holding AG ranks worse than 72.05% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Bachem Holding AG's current ratio for the quarter that ended in Dec. 2025 was 1.79.
Bachem Holding AG has a current ratio of 1.79. It generally indicates good short-term financial strength.
The historical rank and industry rank for Bachem Holding AG's Current Ratio or its related term are showing as below:
BCHMF'
s Current Ratio Range Over the Past 10 Years
Min: 1.57 Med: 2.75 Max: 6.2
Current: 1.79
During the past 13 years, Bachem Holding AG's highest Current Ratio was 6.20. The lowest was 1.57. And the median was 2.75.
BCHMF's Current Ratio is ranked worse than 72.05% of 1417
companies
in the Biotechnology industry
Industry Median: 3.89
vs BCHMF: 1.79
Bachem Holding AG (OTCPK:BCHMF) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Bachem Holding AG Current Ratio Related Terms
Bachem Holding AG Current Ratio Historical Data
* Premium members only.
The historical data trend for Bachem Holding AG's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BCHMF vs VRTX, REGN, ALNY: Current Ratio Comparison
For the Biotechnology subindustry, Bachem Holding AG's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bachem Holding AG Current Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Bachem Holding AG's Current Ratio distribution charts can be found below:
* The bar in red indicates where Bachem Holding AG's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bachem Holding AG (BCHMF) has a Current Ratio of 1.79 as of Dec. 2025. This is 35% below median its historical median of 2.75. Over the past decade, Bachem Holding AG's Current Ratio has ranged from 1.57 to 6.20. According to the industry distribution chart, Bachem Holding AG ranks #1021 out of 1417 companies in the Biotechnology industry, placing it in the top 72.1%.
Is Bachem Holding AG's Current Ratio too high?
Bachem Holding AG's current Current Ratio of 1.79 is 35% below median its 10-year median of 2.75. Over the past 10 years, this metric has ranged from a low of 1.57 to a high of 6.20. The Biotechnology industry median Current Ratio is 3.89. Bachem Holding AG's value of 1.79 is 54% below this industry median. Based on the distribution chart, Bachem Holding AG ranks #1021 out of 1417 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Bachem Holding AG has a GF Score™ of 91/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Bachem Holding AG's Current Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Bachem Holding AG ranks #1021 out of 1417 companies for Current Ratio. This places Bachem Holding AG in the lower half of its industry. The industry median Current Ratio is 3.89. Bachem Holding AG's value of 1.79 is 54% below this benchmark. Historically, Bachem Holding AG's own Current Ratio has ranged from 1.57 to 6.20 over the past decade. While the company's 10-year median is 2.75 vs. the industry median of 3.89, Bachem Holding AG has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Biotechnology company?
The median Current Ratio among Biotechnology companies is 3.89, based on 1,417 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bachem Holding AG's current Current Ratio of 1.79 is 54% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Current Ratio is 3.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bachem Holding AG's current Current Ratio is 1.79, which is 35% below median its own 10-year median of 2.75. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bachem Holding AG stock overvalued right now?
Based on GuruFocus' analysis, Bachem Holding AG (BCHMF) is currently considered Modestly Undervalued. The stock's GF Value™ is $98.14, compared to a current price of $87.34 — trading 11% below its estimated fair value. The current Current Ratio is 1.79, which is 35% below median its 10-year median of 2.75 and 54% below the Biotechnology industry median of 3.89. Bachem Holding AG's overall GF Score™ is 91/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Bachem Holding AG (BCHMF), the current Current Ratio is 1.79 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bachem Holding AG (BCHMF) Overvalued in 2026?
Based on GuruFocus' analysis, Bachem Holding AG stock appears to be undervalued.
The current stock price of $87.34 is trading 11% below its estimated GF Value™ of $98.14.
GuruFocus considers Bachem Holding AG to be Modestly Undervalued.
Key valuation signals for BCHMF:
Current Ratio: 1.79 (35% below median its 10-year median of 2.75)
GF Value™: $98.14 vs. price of $87.34 (11% below fair value)
Industry Position: 54% below the Biotechnology median (#1021 of 1417)
No single metric tells the full story. See the BCHMF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bachem Holding AG is a biochemical company that provides services to the pharmaceutical and biotechnology industry. It focuses on specializing in the development and manufacture of peptides and oligonucleotides. The group markets its products under the Bachem and Clinalfa brands. Its products and services are CMC Development, Commercial API, Research and Specialities, and Services and Capabilities. Geographically, it operates in Switzerland, USA, Ireland, Denmark, United Kingdom, and Rest of the World.
91GF Score
Get the complete analysis for BCHMF
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BCHMF has been successfully added to your 
